Extrait

To determine the efficacy of deforolimus in patients with KRAS mutant NSCLC who have progressed after two prior chemotherapy regimens compared to placebo by progression free survival analysis of randomized patients who have stable disease after an 8-week lead-in treatment with deforolimus.

Critère d'inclusion

• Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations

Liens

• euctr
• ictrp
• ictrp
• ictrp
• euctr
• ictrp
• euctr
• euctr
• euctr